AARTI DRUGS LTD.

Aarti Drugs Ltd has updated its authorized personnel for determining materiality of events and making disclosures to stock exchanges, effective October 1, 2026. This change follows recent shifts in the company's directorate and management. Shri Adhish P. Patil (Managing Director), Shri Harshit M. Savla (Jt. Managing Director), and Rushikesh V. Deole (Company Secretary and Compliance Officer) are now designated for these responsibilities. The company has also made this information available on its website.

Aarti Drugs Ltd has announced significant changes in its Directorate and Key Managerial Personnel. Shri Prakash M. Patil has ceased to hold the positions of Chairman, Managing Director, and Chief Executive Officer, effective September 30, 2026, due to his decision to take early retirement. Concurrently, Shri Adhish P. Patil has been promoted to the position of Managing Director, effective October 1, 2026. As a result of this promotion, Shri Adhish P. Patil has relinquished his role as Chief Financial Officer, also effective September 30, 2026. The company intends to appoint a new CFO in due course.

Aarti Drugs Ltd has announced the closure of its trading window in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015. The window will be shut from October 1, 2026, until 48 hours after the declaration of the financial results for the quarter and half-year ended September 30, 2026. This measure is standard practice to prevent insider trading during sensitive financial reporting periods.

Aarti Drugs Ltd has announced significant changes in its board and management following its 41st Annual General Meeting (AGM) held on September 26, 2026. Shri Uday Moreshwar Patil has ceased to be a Whole-time Director, not seeking re-appointment. Shri Nilesh Bhalchandra Patil has been appointed as a Director and Whole-time Director. Shri Adhish Prakash Patil will join as Director and Managing Director from October 1, 2026. Several key personnel, including Shri Harshit Manilal Savla (Joint Managing Director), Shri Harit Pragji Shah (Whole-time Director), and Independent Directors Shri Hasmukh Bhavanji Dedhia, Shri Sandeep Madhusudan Joshi, and Shri Ajit Eledath Venugopalan, have been re-appointed for varying terms. The company confirmed that none of the individuals are debarred from directorship and that independent directors meet the required criteria.

Aarti Drugs Ltd has announced its 41st Annual General Meeting (AGM) to be held on Saturday, September 26, 2026, at 11:00 a.m. (IST) through Video Conferencing (VC) / Other Audio Visual Means (OAVM). The company will also share its Annual Report for the Financial Year 2025-26 with shareholders electronically. The report highlights significant progress in FY 2025-26, including the commencement of commercial production at the Sayakha facility, increased Salicylic Acid production at Tarapur, and expanded regulatory approvals from USFDA, UK MHRA, and EU GMP, contributing to 73% of revenues. Investments in manufacturing, backward integration, and a record-low debt-to-equity ratio are noted as strengthening the company's platform for future growth.

Aarti Drugs Limited has submitted its Business Responsibility and Sustainability Report (BRSR) for the Financial Year 2025-26, as per SEBI regulations. The report details the company's corporate identity, registered and corporate addresses, contact information, and financial year reporting period. It covers business activities, primarily manufacturing and marketing of pharmaceuticals and chemical products, which account for 100% of turnover. Key products include APIs (89% of turnover), specialty chemicals (8%), and intermediates (3%). The company operates 13 plants and 2 offices nationally, serving 28 states and 8 union territories, with exports contributing approximately 38% of revenue to over 100 countries. Employee details as of March 31, 2026, show a total of 1496 employees and 1335 workers. The BRSR is available on the company's website.

Aarti Drugs Ltd has filed its Annual Report for the Financial Year 2025-26, along with the notice for its 41st Annual General Meeting (AGM) scheduled for September 26, 2026. The report highlights the company's strategic investments translating into operational progress, including the commencement of commercial production at the Sayakha facility, increased Salicylic Acid production at Tarapur, and expanded global regulatory approvals (USFDA, UK MHRA, EU GMP) which contributed 73% of revenues. The company also noted progress on its solar power project and a record-low debt-to-equity ratio, positioning it for future growth despite market challenges.

Aarti Drugs Limited's Board of Directors has approved the 'Aarti Drugs Limited Performance Stock Option Plan 2026' (PSOP 2026). The plan allows for the creation and grant of up to 8,00,000 Performance Stock Options, convertible into an equal number of equity shares. This is subject to shareholder approval and compliance with SEBI regulations. The board meeting where this was decided commenced at 11:30 AM and concluded at 12:20 PM on August 27, 2026.

Aarti Drugs Ltd has announced the closure of its trading window from August 25, 2026, to August 29, 2026. This closure is in anticipation of a Board of Directors meeting scheduled for August 27, 2026. The primary agenda for this meeting is to consider and approve the 'Aarti Drugs Limited – Performance Stock Option Plan 2026', along with related matters. The company has cited SEBI (Prohibition of Insider Trading) Regulations, 2015, and its internal code of conduct as reasons for the trading window restriction. The information is also available on the company's website.

Aarti Drugs Ltd has announced that its Board of Directors will convene on August 27, 2026. The primary agenda item is to consider and approve the 'Aarti Drugs Limited – Performance Stock Option Plan 2026'. The meeting will also address related and incidental matters. In compliance with SEBI regulations and the company's insider trading code, the trading window will be closed from August 25, 2026, to August 29, 2026. Further details are available on the company's website.